Evercore ISI Head of U.S. Public Policy and Political Strategy Research Sarah Bianchi joins Yahoo Finance’s Akiko Fujita to discuss the latest stimulus negotiations in Congress, as Republicans delay the unveiling of their $1 trillion stimulus plan to next week.

from Yahoo Finance https://ift.tt/2BstXWe

Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.Although there were promising updates from some coronavirus vaccine makers, negative headlines plagued Novavax, Inc. (NASDAQ: NVAX) and Moderna Inc (NASDAQ: MRNA), sending their stocks lower by 4.7% and 23%, respectively, for the week.The week saw the listing of 4 biopharma companies on the Nasdaq, which raised a combined $772.9 million.Here are the key catalysts for the unfolding week.Conferences: Alzheimer's Association International Conference, or AAIC, to be held virtually: July 27-31PDUFA Dates The FDA is set to rule on Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) NDA for UX007, its investigational drug for long-chain fatty acid oxidation disorders. (Friday)GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) has a PDUFA action date, with the FDA due to announce its verdict on the company's sNDA for Epidiolex for the treatment of seizures associated with tuberous sclerosis complex. (Friday)Clinical Readouts AAIC Presentations: Alector Inc (NASDAQ: ALEC): preliminary data from a Phase 2 open-label study evaluating AL001 in individuals with frontotemporal dementia (Tuesday)Eisai Co., Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB): latest data of the investigational anti-amyloid beta protofibril antibody BAN2401; Biogen will also make an oral presentation of the previously publicized topline results of Phase III studies EMERGE and ENGAGEAC Immune SA (NASDAQ: ACIU): Key data on its alpha-synuclein-positron emission tomography tracer program along with a second oral presentation of the Phase 1b trial of the anti-Abeta vaccine ACI-24 in Down syndromeSee Also: How Moderna's Patent Challenge Loss Could Impact Coronavirus Vaccine ProgramStandalone releases: Tcr2 Therapeutics Inc (NASDAQ: TCRR) said it plans to discuss initial data from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for patients with mesothelin-expressing solid tumors. (before the market open, Monday)Genocea Biosciences Inc (NASDAQ: GNCA) is scheduled to present initial clinical data on the first 5 patients from Part B of the Phase 1/2 study, which is exploring the combination of GEN-009 and immune checkpoint inhibitor-based regimens in advanced solid tumors. (Friday)Pending mid-2020 Releases: Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI): top-line results from Cohort 2 of the ZENITH20 trial evaluating poziotinib in previously treated HER2 non-small cell lung cancer patientsIntra-Cellular Therapies Inc (NASDAQ: ITCI): top-line results from a Phase 3 study evaluating lumateperone as adjunctive therapy in bipolar depression.BioXcel Therapeutics Inc (NASDAQ: BTAI): top-line results from a Phase 1/2b trial of BXCL501 for the acute treatment of agitation associated with geriatric dementia.Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY): top-line results from the ILLUMINATE-B Phase 3 study of lumasiran in primary hyperoxaluria type 1 patients less than six years of age with preserved renal function.Karuna Therapeutics Inc (NASDAQ: KRTX): data from Phase 1b clinical trial of KarXT in experimentally induced painAkari Therapeutics PLC (NASDAQ: AKTX): interim update on the Part B placebo-controlled efficacy arm of the study of nomacopan eye drops in atopic keratoconjunctivitisSeres Therapeutics Inc (NASDAQ: MCRB): Data from SER-109 Phase 3 study in recurrent C. difficile infectionMesoblast (NASDAQ: MESO): data from a Phase 3 randomized controlled trial of Revascor for advanced heart failureAkebia Therapeutics Inc (NASDAQ: AKBA: ) top-line data from the global Phase 3 studies evaluating the safety and efficacy of vadadustat in adult patients not on dialysis with anemia due to chronic kidney diseaseView more earnings on IBBAnavex Life Sciences Corp (NASDAQ: AVXL): top-line results from the Phase 2 study of ANAVEX 2-73 in Parkinson's disease dementia Phase 2 trialBIOLINERX LTD/S ADR (NASDAQ: BLRX): Progression-free survival and overall survival data from the triple combination arm of the COMBAT/KEYNOTE-202 Phase 2a study of BL-8040 in combination with Merck & Co., Inc.'s (NYSE: MRK) Keytruda in advanced second-line pancreatic cancerArcus Biosciences Inc (NYSE: RCUS): preliminary data from Phase 1b expansion trials involving combinations with AB928 in multiple tumor types and settingsHomology Medicines Inc (NASDAQ: FIXX): additional data from Phase 1/2 pheNIX gene therapy trial for phenylketonuriaVaxart Inc (NASDAQ: VXRT): data from universal Influenza vaccine collaboration with Johnson & Johnson's (NYSE: JNJ) Janssen unitAlbireo Pharma Inc (NASDAQ: ALBO): top-line results from the Phase 3 PEDFIC 1 trial that is evaluating Odevixibat in progressive familial intrahepatic cholestasis; top-line data from the Phase 3 trial of elobixibat in non-alcoholic steatohepatitis and non-alcoholic fatty liver diseaseresTORbio, Inc. (NASDAQ: TORC): data from the four completed cohorts of the Phase 1b/2a trial of RTB101 in combination with sirolimus in Parkinson's diseaseEarnings Monday Medpace Holdings Inc (NASDAQ: MEDP) (after the close)Tuesday Exagen Inc (NASDAQ: XGN) (before the market open) Pfizer Inc. (NYSE: PFE) (before the market open) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (before the market open) Masimo Corporation (NASDAQ: MASI) (after the close) AtriCure Inc. (NASDAQ: ATRC) (after the close) Amgen, Inc. (NASDAQ: AMGN) (after the close) NeoGenomics, Inc. (NASDAQ: NEO) (after the close) DexCom, Inc. (NASDAQ: DXCM) (after the close) Infinity Pharmaceuticals Inc. (NASDAQ: INFI) (after the close)Wednesday Boston Scientific Corporation (NYSE: BSX) (before the market open) United Therapeutics Corporation (NASDAQ: UTHR) (before the market open) Hologic, Inc. (NASDAQ: HOLX) (after the close) Alimera Sciences Inc (NASDAQ: ALIM) (after the close) Merit Medical Systems, Inc. (NASDAQ: MMSI) (after the close)Thursday Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) (before the market open) Blueprint Medicines Corp (NASDAQ: BPMC) (before the market open) Iradimed Corp (NASDAQ: IRMD) (before the market open) •Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) before the market open) Agios Pharmaceuticals Inc (NASDAQ: AGIO) (before the market open) Eli Lilly And Co (NYSE: LLY) (before the market open) Elanco Animal Health Inc (NYSE: ELAN) (before the market open) Evelo Biosciences Inc (NASDAQ: EVLO) (before the market open) BioTelemetry Inc (NASDAQ: BEAT) (after the close) MacroGenics Inc (NASDAQ: MGNX) (after the close) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) (after the close) Emergent Biosolutions Inc (NYSE: EBS) (after the close) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) (after the close) Anika Therapeutics Inc (NASDAQ: ANIK) (after the close) Gilead Sciences, Inc. (NASDAQ: GILD) (after the close) Natus Medical Inc (NASDAQ: NTUS) (after the close) Retrophin Inc (NASDAQ: RTRX) (after the close) Veracyte Inc (NASDAQ: VCYT) (after the close) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) (after the close) Globus Medical Inc (NYSE: GMED) (after the close) Quidel Corporation (NASDAQ: QDEL) (after the close) EXACT Sciences Corporation (NASDAQ: EXAS) (after the close) Tandem Diabetes Care Inc (NASDAQ: TNDM) (after the close)Friday AbbVie Inc (NYSE: ABBV) (before the market open) ImmunoGen, Inc. (NASDAQ: IMGN) (before the market open)IPOs Cambridge, Massachusetts-based AlloVir, which develops allogenic off-the-shelf virus-specific T cell therapy candidates targeting 12 devastating viruses, proposes to offer 14.75 million shares in an IPO, with the price range estimated between $16 and $18. The company has applied for listing its shares on the Nasdaq under the ticker symbol ALVR.Woodcliff Lake, New Jersey-based PaxMedica, Inc. has filed with the SEC to offer 2.5 million shares to be priced between $5.50 and $6.50. The company is an early clinical-stage biopharma focusing on the development of anti-purinergic therapies for the treatment of neurodevelopmental disorders, including autism spectrum disorder, and Fragile X syndrome tremor-ataxia. It has applied for listing its shares on the Nasdaq under the ticker symbol PXMD.See more from Benzinga * The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs * The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results * The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

from Yahoo Finance https://ift.tt/2P1bQK0

from Yahoo Finance https://ift.tt/2BuS46C

The U.S.-based drug maker said the additional funding will support its late-stage clinical development including the expanded Phase 3 study of Moderna’s vaccine candidate. In April, Moderna had received $483 million from the U.S. federal agency that funds disease-fighting technology, when the experimental vaccine was in an early-stage trial conducted by the U.S. National Institutes of Health.

from Yahoo Finance https://ift.tt/39uZnYA

Sal Gilbertie, Teucrium Funds CEO, joins Yahoo Finance’s On the Move to talk about the global demand for U.S. farming and agricultural products amid the coronavirus pandemic.

from Yahoo Finance https://ift.tt/3hzzU33

Investors this week are gearing up for a busy week of earnings, economic data reports and the Federal Reserve’s July monetary policy meeting.

from Yahoo Finance https://ift.tt/32XOkpE

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Pfizer Inc…

from Yahoo Finance https://ift.tt/300JOF3

“June quarter results likely to outperform consensus estimates on the back of better than expected hardware sell-in. We currently forecast June quarter revenue and EPS of $55.1B and $2.18, 7% and 8% above current consensus estimates, respectively,” said Morgan Stanley.

from Yahoo Finance https://ift.tt/3jAQscV

Freeport-McMoRan Inc. (NYSE:FCX) shareholders are probably feeling a little disappointed, since its shares fell 3.4…

from Yahoo Finance https://ift.tt/2WV7YyA

Prior to the renaissance of online-sports gambling, Penn National Gaming (NASDAQ:PENN) was primarily known as an owner and operator of regional casino properties. That was a highly profitable venture until the novel coronavirus kept gamblers away from crowded casinos, which in turn put pressure on the price of PENN stock.Source: Casimiro PT / Shutterstock.com While the traditional casino business was hit hard by lockdowns and social distancing, e-commerce thrived during the first half of the year. The gaming industry had to adapt to this new environment or risk being put out of business.Penn National Gaming is adapting and making the best of a challenging situation. Sure, PENN stock can be viewed as a "reopening trade," as America's restrictions on in-person gambling are gradually being lifted. An equally strong argument, however, can be made that Penn National is a compelling wager on online sports gambling with strong breakout potential.InvestorPlace – Stock Market News, Stock Advice & Trading Tips A Closer Look at PENN StockIt's difficult to predict exactly when the stock's breakthrough moment will occur. Yet, based on its historical price action, we can at least discern the price point that needs to be breached.The bulls have made several runs for the $38 level this year. However, each and every time, the bulls were rejected, and the share price fell quickly. It's frustrating, no doubt, but that's the name of the game. as sometimes it takes many attempts before a resistance level is finally breached. * 10 Cybersecurity Stocks We Need Now More Than Ever What the bulls need now is an increase in the daily trading volume of PENN stock as well as upward momentum in the share price. But once that $38 price point is broken with conviction, it's off to the races, and $45 should be the bulls' next target. Reopenings Will Drive GrowthWhile the headline story should be the online-sports angle, I would be remiss to ignore the possibility of PENN stock benefiting from the reopening of the economy. After all, the fact that America's casinos are being allowed to open again should be eventful for Penn National Gaming and its stakeholders. Penn National Gaming's recovery in this domain will take place on a state-by-state basis.To provide a couple of examples, we can observe that not long ago, the company announced two significant reopenings. One was the Plainridge Park Casino, located in Massachusetts. The other was Maine's Hollywood Casino Bangor.After these two reopenings, 37 of Penn National's 41 gaming and racing properties are now up and running. So the company is not quite back to its pre-pandemic levels yet. Nevertheless, the owners of PENN stock should be encouraged by the progress that's being made. Gambling Hasn't Gone AwayAlthough the novel coronavirus kept people out of casinos, not everyone has stopped gambling. They're just doing it differently now. During the shutdowns, some bored people were introduced to online gaming, and now that market is thriving.Penn National Gaming still has its 41 gaming and racing properties and 19 states, but the company isn't wholly relying on in-person gambling. The acquisition of a 36% stake in sports-gambling website Barstool Sports proves that Penn National Gaming is ready and willing to adapt to shifts in gambling trends.When warrants are factored into the equation, Penn National Gaming's stake in Barstool Sports could conceivably increase to 50%. It's a savvy move, as Barstool Sports has 66 million monthly active users, along with almost 100 million followers on social media.Through this partnership, Penn National Gaming plans to introduce Barstool Sportsbook, a sports-gambling app, this fall. There will also be Barstool Bets, a service designed to provide gambling advice and news.This collaboration will undoubtedly expand Penn National Gaming's customer base. Just as importantly, it will keep the company in-line with recent gaming trends. If online betting is the future of gambling, then Penn National Gaming is getting ahead of the curve. The Bottom LinePenn National Gaming's investment in Barstool Sports is the smartest move that the company could make right now. Thus, PENN stock's breakout is probably coming soon as the shift to online sports betting has plenty of momentum.David Moadel has provided compelling content – and crossed the occasional line – on behalf of Crush the Street, Market Realist, TalkMarkets, Finom Group, Benzinga, and (of course) InvestorPlace.com. He also serves as the chief analyst and market researcher for Portfolio Wealth Global and hosts the popular financial YouTube channel Looking at the Markets. As of this writing, David Moadel did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post Penn National's Barstool Stake Will Take It to Another Level appeared first on InvestorPlace.

from Yahoo Finance https://ift.tt/3f44kJ7